BR112015004190A2 - composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada - Google Patents

composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada

Info

Publication number
BR112015004190A2
BR112015004190A2 BR112015004190A BR112015004190A BR112015004190A2 BR 112015004190 A2 BR112015004190 A2 BR 112015004190A2 BR 112015004190 A BR112015004190 A BR 112015004190A BR 112015004190 A BR112015004190 A BR 112015004190A BR 112015004190 A2 BR112015004190 A2 BR 112015004190A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
release pharmaceutical
sustained release
sustained
producing
Prior art date
Application number
BR112015004190A
Other languages
English (en)
Inventor
Yano Hideki
Yoshida Kazuhiro
Fukui Sachiko
Yada Shuichi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112015004190A2 publication Critical patent/BR112015004190A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo farmacãšutica de liberaã‡ãƒo sustentada, e, mã‰todo para produzir uma composiã‡ãƒo farmacãšutica de liberaã‡ãƒo sustentada” um objetivo ã© fornecer uma composiã§ã£o farmacãªutica de liberaã§ã£o sustentada contendo cloridrato de hidromorfona ou hidrato de cloridrato de oxicodona para administraã§ã£o oral que apresenta confiavelmente seu principal efeito farmacolã³gico e tem excelente estabilidade de formulaã§ã£o que evita liberaã§ã£o rã¡pida da dose do principal medicamento, tal como resistãªncia a ã¡lcool. a presente invenã§ã£o fornece uma composiã§ã£o farmacãªutica de liberaã§ã£o sustentada compreendendo (a) cloridrato de hidromorfona ou hidrato de cloridrato de oxicodona, (b) succinato do acetato de hidroxipropil metilcelulose com um tamanho mediano (d ) de 40 m ou 50 menos, (c) hidroxipropil celulose e (d) um sacarã­deo, em que a razã£o do teor do componente (c) para o componente (b) em peso na composiã§ã£o, (c)/(b), ã© 11/3 a 3/11.
BR112015004190A 2012-09-03 2013-09-02 composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada BR112015004190A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012192783 2012-09-03
PCT/JP2013/073519 WO2014034929A1 (ja) 2012-09-03 2013-09-02 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物

Publications (1)

Publication Number Publication Date
BR112015004190A2 true BR112015004190A2 (pt) 2017-07-04

Family

ID=50183727

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004190A BR112015004190A2 (pt) 2012-09-03 2013-09-02 composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada

Country Status (12)

Country Link
US (1) US9827199B2 (pt)
EP (1) EP2893928B1 (pt)
JP (1) JP6129184B2 (pt)
KR (1) KR102127625B1 (pt)
CN (1) CN104768552A (pt)
BR (1) BR112015004190A2 (pt)
CA (1) CA2883077C (pt)
ES (1) ES2706994T3 (pt)
HK (1) HK1210053A1 (pt)
RU (1) RU2665372C2 (pt)
TW (1) TWI566786B (pt)
WO (1) WO2014034929A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
JP7365157B2 (ja) * 2018-07-17 2023-10-19 沢井製薬株式会社 イミダフェナシン含有錠剤の製造方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI89457C (fi) 1986-04-30 1993-10-11 Chugai Pharmaceutical Co Ltd Foerfarande foer framstaellning av ett preparat som innehaoller ett aluminiumsalt av en sackarossulfatester
US5547943A (en) 1986-04-30 1996-08-20 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparation
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
AU7375598A (en) 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
IL136028A0 (en) 1997-11-12 2001-05-20 Boehringer Mannheim Pharm Corp Novel oral dosage form for carvedilol
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
ES2199857T3 (es) 1999-08-26 2004-03-01 Neurocrine Biosciences, Inc. Composiciones sedantes-hipnoticas de liberacion controlada y metodos relacionados con ellas.
JP4641696B2 (ja) 1999-09-30 2011-03-02 大塚製薬株式会社 消化管下部溶解性コーティング製剤
JP2001270821A (ja) 2000-03-23 2001-10-02 Eisai Co Ltd 服用感が優れた散剤
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
IN191028B (pt) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
CA2451605C (en) 2001-06-20 2010-08-10 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
AU2002328596B2 (en) 2001-08-09 2007-09-20 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
JP4644397B2 (ja) 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
HRP20020124A2 (en) 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
JP2004026750A (ja) 2002-06-27 2004-01-29 Nippon Shinyaku Co Ltd 薬物の安定化法
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical PREPARATION FOR PROLONGED RELEASE
US20040052844A1 (en) 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
WO2004041252A1 (en) 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
AU2003292828B9 (en) 2002-12-25 2009-10-01 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
EP1640006A4 (en) 2003-06-27 2012-04-04 Otsuka Pharma Co Ltd PARTICLES WITH DELAYED MEDICAMENT RELIEF AND MANUFACTURING METHOD THEREFOR
WO2005048979A2 (en) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
WO2005051325A2 (en) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20060008418A1 (en) 2004-07-12 2006-01-12 Solidtech Animal Health, Inc. Packaging and method for solid dose administration of an electronic identification chip and medicaments
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US20060280789A1 (en) 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060159753A1 (en) 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
AU2006263337A1 (en) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
RU2433821C2 (ru) 2005-08-30 2011-11-20 Пирамал Лайф Сайнсис Лимитед Фармацевтическая композиция метформина с длительным высвобождением и способ ее получения
HUE029336T2 (en) 2005-09-16 2017-02-28 Daiichi Sankyo Co Ltd For the preparation of an optically active diamine derivative and process
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8652529B2 (en) * 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
WO2007113857A2 (en) 2006-04-05 2007-10-11 Cadila Healthcare Limited Modified release clopidogrel formulation
CN101489560B (zh) 2006-04-26 2015-11-25 苏佩努斯制药公司 具有s形释放曲线的奥卡西平控释制剂
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US20080181947A1 (en) 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
CN100563637C (zh) 2006-10-13 2009-12-02 北京红林制药有限公司 一种控释给药的药芯组合物和控释制剂及其制备方法
JP2008169173A (ja) 2007-01-15 2008-07-24 Kissei Pharmaceut Co Ltd 炭水化物分解酵素阻害剤の胃内滞留型徐放性製剤
US20100112053A1 (en) 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
KR20080076382A (ko) 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
CN101652139A (zh) 2007-03-29 2010-02-17 第一三共株式会社 药物组合物
JP2011500553A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
JP2011502140A (ja) 2007-10-29 2011-01-20 ルピン・リミテッド トルテロジンの制御放出型医薬組成物
SI2057984T1 (sl) * 2007-11-09 2010-04-30 Acino Pharma Ag Retardne tablete s hidromorfonom
AU2008338207A1 (en) * 2007-12-17 2009-06-25 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
SI22849A (sl) 2008-08-01 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Ropinirolni pripravek
FR2951378B1 (fr) 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
WO2011084593A2 (en) * 2009-12-17 2011-07-14 Cima Labs Inc. Abuse-resistant formulations
JP5714562B2 (ja) 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
EP2540317A4 (en) 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
ES2706880T3 (es) * 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
EP2538928B1 (en) * 2010-02-24 2017-05-03 Cima Labs Inc. Abuse-resistant formulations
SE1251371A1 (sv) * 2010-05-10 2012-12-27 Euro Celtique Sa Farmaceutiska kompositioner innefattande hydromorfon och naloxon

Also Published As

Publication number Publication date
TW201414509A (zh) 2014-04-16
RU2665372C2 (ru) 2018-08-29
KR20150045446A (ko) 2015-04-28
KR102127625B1 (ko) 2020-06-29
TWI566786B (zh) 2017-01-21
US9827199B2 (en) 2017-11-28
HK1210053A1 (en) 2016-04-15
CA2883077C (en) 2017-03-07
JP6129184B2 (ja) 2017-05-17
ES2706994T3 (es) 2019-04-02
CA2883077A1 (en) 2014-03-06
CN104768552A (zh) 2015-07-08
US20150231083A1 (en) 2015-08-20
EP2893928A1 (en) 2015-07-15
EP2893928B1 (en) 2018-10-24
EP2893928A4 (en) 2016-04-27
JPWO2014034929A1 (ja) 2016-08-08
RU2015112122A (ru) 2016-10-20
WO2014034929A1 (ja) 2014-03-06

Similar Documents

Publication Publication Date Title
BR112013003581B8 (pt) Composição farmacêutica ou nutracêutica gastro resistente, que compreende um ou mais sais do ácido algínico, e seu processo de produção
BRPI0922804B8 (pt) composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável
BR112015023409A8 (pt) complexo iônico, composição farmacêutica compreendendo o referido complexo, seu uso e métodos de produção do referido complexo
BR112015032623A8 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BRPI0613499A8 (pt) formulação de comprimido farmacêutico de 1[(3-hidróxi-adamant-1-ilamino)-acetil]- pirrolidino-2(s)-carbonitrila de liberação modificada, comprimido em multicamada, comprimido farmacêutico e cápsula contendo a mesma, processo de produção da mesma, seu uso, processo de preparação de comprimido bem como forma de dosagem farmacêutica
BR112015002372A2 (pt) composições e métodos para a redução do teor de álcool no sangue
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BR112014029708A8 (pt) Composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
MX346879B (es) Formulaciones de ketorolaco listas para su uso.
BR112012030024A2 (pt) compostos, processo para a preparação de um composto, medicamento
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
BR112013004416A2 (pt) agente terapêutico para enfisema pulmonar
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
BRPI0915119B8 (pt) uso de iota carragenano
BR112014016472A2 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112015007360A8 (pt) Composição farmacêutica, e, método para a preparação de uma droga de combinação
BR112013026153A2 (pt) Composição farmacêutica; uso de pelo menos um éter de celulose não iônico; método parapreparar uma composição farmacêutica; método para tratar e/ou prevenir um distúrbioclimatérico; uso de uma composição farmacêutica; e kit
BR112015004190A2 (pt) composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada
BR112012026714A2 (pt) pastilhas de eritritol e isomalte

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements